Dishman Carbogen Amcis Limited has announced that its wholly-owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., successfully completed an unannounced Good Manufacturing Practice (GMP) inspection by China’s National Medical Products Administration (NMPA). Conducted on April 14, 2026, the audit of the Shanghai site concluded with zero observations, affirming the facility’s strict adherence to international quality standards and its operational readiness for global pharmaceutical manufacturing demands.
Successful Inspection Outcome
The Shanghai facility of CARBOGEN AMCIS has cleared a rigorous unannounced GMP inspection performed by the Chinese health authorities. The audit, which took place on April 14, 2026, involved an in-depth assessment of the site’s API manufacturing operations, quality control laboratories, and overall quality management systems. The result was highly positive, with no observations or issues identified by the regulators.
Strategic Significance
The successful outcome serves as a strong validation of the company’s global quality culture and internal operational standards. By passing this unannounced check, the site demonstrated its ability to consistently maintain high-level compliance under routine, day-to-day conditions. This milestone reinforces the confidence of global partners in the Shanghai site’s capability to support API manufacturing and process development activities.
Leadership Commentary
Management highlighted that this achievement reflects the deep expertise of the local team and the maturity of their quality systems. According to the company, this result not only confirms their commitment to GMP standards but also ensures the site remains a reliable and competitive partner for pharmaceutical companies within China and across the global markets it serves.
Source: BSE
